3-((Dimethylaminomethylene)-6,6-dimethyltetrahydropyran-2,4-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 3-((Dimethylaminomethylene)-6,6-dimethyltetrahydropyran-2,4-dione
• 英文别名: (3E)-3-(dimethylaminomethylidene)-6,6-dimethyloxane-2,4-dione
• 化学式: C₁₀H₁₅NO₃
• 分子量: 197.23
• InChiKey: VFKXLGPKVYZZJF-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：US10836759B2

  公开（公告）日：2020-11-17

  A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.

  一种式 II 的化合物或其药学上可接受的盐，其中 CyN 是通过氮原子结合的环胺基；X 是 C 或 N；R1 和 R2 各自独立地是卤素、CN、CF3、CHF2、CH2F、C1-C10 烷基、C1-C10 烷氧基、二(C1-C5 烷基)氨基；m和n各自独立地为1、2或3，代表单键或双键，其中不包括3-(4-(4-氯苯基)噻唑-2-基)-1-(2-乙基-5-甲氧基苯基)-6-(2-甲基丙-1-烯-1-基)-5-(哌嗪-1-羰基)吡啶-2(1H)-酮异构体的外消旋混合物。
• MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER
  申请人：The United States of America, as represented by The Secretary, Department of Health and Human Services

  公开号：EP3237385B1

  公开（公告）日：2021-11-24
• THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER
  申请人：THE UNITED STATED OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE

  公开号：US20190241551A1

  公开（公告）日：2019-08-08

  A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R 1 and R 2 are each independently a halogen, CN, CF 3 , CHF 2 , CH 2 F, a C 1 -C10alkyl group, a C1-C 10 alkoxy group, a di(C 1 -C 5 alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.
• [EN] MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER<br/>[FR] INHIBITEURS D'IDH1 MUTANTS UTILES POUR TRAITER LE CANCER
  申请人：USA

  公开号：WO2016106331A1

  公开（公告）日：2016-06-30

  Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.